BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Aronson KI, Danoff SK, Russell AM, Ryerson CJ, Suzuki A, Wijsenbeek MS, Bajwah S, Bianchi P, Corte TJ, Lee JS, Lindell KO, Maher T, Martinez FJ, Meek PM, Raghu G, Rouland G, Rudell R, Safford MM, Sheth JS, Swigris JJ. Patient-centered Outcomes Research in Interstitial Lung Disease: An Official American Thoracic Society Research Statement. Am J Respir Crit Care Med 2021;204:e3-e23. [PMID: 34283696 DOI: 10.1164/rccm.202105-1193ST] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 Wijsenbeek MS, Moor CC, Johannson KA, Jackson PD, Khor YH, Kondoh Y, Rajan SK, Tabaj GC, Varela BE, van der Wal P, van Zyl-Smit RN, Kreuter M, Maher TM. Home monitoring in interstitial lung diseases. Lancet Respir Med 2023;11:97-110. [PMID: 36206780 DOI: 10.1016/S2213-2600(22)00228-4] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
2 Lemmers JMJ, Vonk MC, van den Ende CHM. Patient-reported outcomes to assess dyspnoea in interstitial lung disease and pulmonary hypertension: a systematic literature review of measurement properties. Eur Respir Rev 2022;31:220091. [PMID: 36543348 DOI: 10.1183/16000617.0091-2022] [Reference Citation Analysis]
3 Phua G, Tan GP, Phua HP, Lim WY, Neo HY, Chai GT. Health-related quality of life in a multiracial Asian interstitial lung disease cohort. J Thorac Dis 2022;14:4713-24. [PMID: 36647495 DOI: 10.21037/jtd-22-906] [Reference Citation Analysis]
4 Obi ON, Saketkoo LA, Russell AM, Baughman RP. Sarcoidosis: Updates on therapeutic drug trials and novel treatment approaches. Front Med (Lausanne) 2022;9:991783. [PMID: 36314034 DOI: 10.3389/fmed.2022.991783] [Reference Citation Analysis]
5 Wijsenbeek M, Suzuki A, Maher TM. Interstitial lung diseases. The Lancet 2022;400:769-86. [DOI: 10.1016/s0140-6736(22)01052-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
6 Dasouki S, Quach S, Mancopes R, Mitchell SC, Goldstein R, Brooks D, Oliveira A. A Non-Pharmacological Cough Therapy for People with Interstitial Lung Diseases: A Case Report. Physiotherapy Canada. [DOI: 10.3138/ptc-2021-0081] [Reference Citation Analysis]
7 Wijsenbeek M, Molina-Molina M, Chassany O, Fox J, Galvin L, Geissler K, Hammitt KM, Kreuter M, Moua T, O'Brien EC, Slagle AF, Krasnow A, Reaney M, Baldwin M, Male N, Rohr KB, Swigris J, Antoniou K. Developing a conceptual model of symptoms and impacts in progressive fibrosing interstitial lung disease to evaluate patient-reported outcome measures. ERJ Open Res 2022;8:00681-2021. [PMID: 35509443 DOI: 10.1183/23120541.00681-2021] [Reference Citation Analysis]
8 Swigris JJ, Bushnell DM, Rohr K, Mueller H, Baldwin M, Inoue Y. Responsiveness and meaningful change thresholds of the Living with Pulmonary Fibrosis (L-PF) questionnaire Dyspnoea and Cough scores in patients with progressive fibrosing interstitial lung diseases. BMJ Open Resp Res 2022;9:e001167. [DOI: 10.1136/bmjresp-2021-001167] [Reference Citation Analysis]
9 Nolan CM, Birring SS. PROMising developments in IPF patient-reported outcome measures. Eur Respir J 2022;59:2102312. [PMID: 35027375 DOI: 10.1183/13993003.02312-2021] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Aronson KI, Suzuki A. Health Related Quality of Life in Interstitial Lung Disease: Can We Use the Same Concepts Around the World? Front Med (Lausanne) 2021;8:745908. [PMID: 34692737 DOI: 10.3389/fmed.2021.745908] [Reference Citation Analysis]
11 . Erratum: Patient-centered Outcomes Research in Interstitial Lung Disease: An Official American Thoracic Society Research Statement. Am J Respir Crit Care Med 2021;204:616. [PMID: 34579621 DOI: 10.1164/rccm.v204erratum1a] [Reference Citation Analysis]